[go: up one dir, main page]

MX2017016199A - Formulacion de anticuerpo anti-cgrp. - Google Patents

Formulacion de anticuerpo anti-cgrp.

Info

Publication number
MX2017016199A
MX2017016199A MX2017016199A MX2017016199A MX2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A
Authority
MX
Mexico
Prior art keywords
headaches
antibody formulation
cgrp antibody
clusters
episodic
Prior art date
Application number
MX2017016199A
Other languages
English (en)
Other versions
MX395147B (es
Inventor
N Sharma Anant
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017016199A publication Critical patent/MX2017016199A/es
Publication of MX395147B publication Critical patent/MX395147B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas para anticuerpos anti-CGRP y métodos para usar los mismos, los cuales son útiles para el tratamiento para migrañas, cefaleas episódicas, cefaleas crónicas, cefaleas en racimos crónicas y cefaleas en racimos episódicos.
MX2017016199A 2015-06-17 2016-06-08 Formulación de anticuerpo anti-cgrp. MX395147B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
PCT/US2016/036407 WO2016205037A1 (en) 2015-06-17 2016-06-08 Anti-cgrp antibody formulation

Publications (2)

Publication Number Publication Date
MX2017016199A true MX2017016199A (es) 2018-03-01
MX395147B MX395147B (es) 2025-03-24

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016199A MX395147B (es) 2015-06-17 2016-06-08 Formulación de anticuerpo anti-cgrp.

Country Status (31)

Country Link
US (3) US11498959B2 (es)
EP (2) EP4470557A3 (es)
JP (1) JP6438599B2 (es)
KR (1) KR102000867B1 (es)
CN (3) CN114948847A (es)
AR (1) AR104847A1 (es)
AU (1) AU2016280555B2 (es)
BR (1) BR112017023374A2 (es)
CA (1) CA2984185A1 (es)
DK (1) DK3310809T3 (es)
EA (1) EA037580B1 (es)
ES (1) ES3000607T3 (es)
FI (1) FI3310809T3 (es)
HR (1) HRP20241660T1 (es)
HU (1) HUE069368T2 (es)
IL (2) IL292562A (es)
JO (1) JO3772B1 (es)
LT (1) LT3310809T (es)
MA (1) MA49726B1 (es)
MD (1) MD3310809T2 (es)
MX (1) MX395147B (es)
MY (1) MY184266A (es)
NZ (1) NZ737046A (es)
PL (1) PL3310809T3 (es)
PT (1) PT3310809T (es)
RS (1) RS66243B1 (es)
SI (1) SI3310809T1 (es)
TW (1) TWI725973B (es)
UA (1) UA120881C2 (es)
WO (1) WO2016205037A1 (es)
ZA (1) ZA201707324B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CA3037661A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CN110621343A (zh) 2017-03-02 2019-12-27 贝丝以色列女执事医疗中心 选择对针对降钙素基因相关肽的抗体有反应的头痛患者
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
IL281693B2 (en) * 2018-09-20 2025-01-01 Teva Pharmaceuticals Int Gmbh Injection spring for old prefilled syringe and auto injector
JOP20210156A1 (ar) 2019-01-08 2023-01-30 H Lundbeck As علاج إسعافي وعلاج سريع للصداع باستخدام أجسام مضادة لـ cgrp
CA3133571A1 (en) * 2019-05-02 2020-11-05 Roger K. Cady Treatment of headache using anti-cgrp antibodies
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9306133A (es) 1992-10-02 1994-04-29 Kabi Pharmacia Ab Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
ATE556591T1 (de) * 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MX2007010971A (es) * 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US8007794B2 (en) * 2005-11-14 2011-08-30 Rinat Neuroscience Corporation Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
RU2009126420A (ru) * 2006-12-11 2011-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Парентеральная лекарственная форма антитела к абета
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
RU2518278C2 (ru) * 2008-09-19 2014-06-10 Пфайзер Инк. Стабильный жидкий препарат антитела
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
ES2719496T3 (es) * 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
PL3831406T3 (pl) * 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
EP2691112B1 (en) * 2011-03-31 2018-05-23 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
CN104093739A (zh) 2011-10-24 2014-10-08 艾伯维公司 针对tnf的免疫结合剂
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
AU2014209994B2 (en) * 2013-01-24 2017-03-16 Glaxosmithkline Intellectual Property Development Limited TNF-alpha antigen-binding proteins
KR102274964B1 (ko) * 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018007214A2 (pt) * 2015-10-30 2018-10-16 Lilly Co Eli anticorpos biespecíficos anti-cgrp/anti-il-23 e usos destes

Also Published As

Publication number Publication date
TW201711697A (zh) 2017-04-01
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
US20180134772A1 (en) 2018-05-17
JP6438599B2 (ja) 2018-12-19
EP4470557A3 (en) 2025-02-26
EP3310809A1 (en) 2018-04-25
HRP20241660T1 (hr) 2025-02-14
US11498959B2 (en) 2022-11-15
EA037580B1 (ru) 2021-04-16
PL3310809T3 (pl) 2025-01-27
UA120881C2 (uk) 2020-02-25
IL292562A (en) 2022-06-01
FI3310809T3 (fi) 2024-12-07
MA49726A (fr) 2020-06-10
CA2984185A1 (en) 2016-12-22
EP3310809B1 (en) 2024-10-16
SI3310809T1 (sl) 2025-03-31
HUE069368T2 (hu) 2025-02-28
ZA201707324B (en) 2020-01-29
KR20180002858A (ko) 2018-01-08
CN107787229A (zh) 2018-03-09
WO2016205037A1 (en) 2016-12-22
CN114948847A (zh) 2022-08-30
LT3310809T (lt) 2025-01-10
PT3310809T (pt) 2024-12-16
DK3310809T3 (da) 2024-12-02
AR104847A1 (es) 2017-08-16
MY184266A (en) 2021-03-30
EP4470557A2 (en) 2024-12-04
EA201792359A1 (ru) 2018-05-31
BR112017023374A2 (pt) 2018-07-24
MX395147B (es) 2025-03-24
HK1245813A1 (en) 2018-08-31
CN118356393A (zh) 2024-07-19
IL255443B (en) 2022-06-01
IL255443A0 (en) 2017-12-31
US20220112277A1 (en) 2022-04-14
NZ737046A (en) 2019-09-27
JO3772B1 (ar) 2021-01-31
KR102000867B1 (ko) 2019-07-16
JP2018517727A (ja) 2018-07-05
AU2016280555B2 (en) 2018-11-15
AU2016280555A1 (en) 2017-11-16
MD3310809T2 (ro) 2025-03-31
MA49726B1 (fr) 2025-02-28
US20230159628A1 (en) 2023-05-25
ES3000607T3 (en) 2025-03-03

Similar Documents

Publication Publication Date Title
MX2017016199A (es) Formulacion de anticuerpo anti-cgrp.
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
BR112019012342A2 (pt) anticorpos il-11
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
IL261163B (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
BR112019012343A2 (pt) anticorpos il-11ra
CO2017003005A2 (es) Anticuerpos anti-mfi2
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
IL262286A (en) Novel immunogenic cd1d binding peptides
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112016019389A8 (pt) Vacina, e, peptídeo
BR112017008097A2 (pt) método para tratar condições oculares
MX2017007338A (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis.
CR20160444A (es) Proteínas de fusión uti
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
BR112016007816A2 (pt) composições peptídicas inovadoras